Sublocade from Indivior - once-monthly injection reshapes US opioid treatment
06.07.2026 - 09:24:57 | ad-hoc-news.de
By Daniel Foster, ad hoc news Bestsellers & Flagships Desk. Reviewed July 06, 2026, 7:30 AM ET. Details in the imprint.
Standing in a clinic waiting room in Newark, the nurse wheels out a small refrigerated tray and says, "This is the Sublocade dose for Mr. Ramirez." The Sublocade prefilled syringe looks unassuming, but for many patients it means one injection, once a month, instead of juggling daily pills or films.
What Sublocade actually is
Sublocade is Indivior’s once-monthly injectable formulation of buprenorphine, approved by the FDA for the treatment of moderate to severe opioid use disorder in adult patients who have been stabilized on a transmucosal buprenorphine product. The drug is supplied as a sterile, clear to opalescent solution that forms a solid depot under the skin after injection, slowly releasing buprenorphine over a month.
Indivior describes Sublocade as a subcutaneous injection given into the abdominal region, available in 100 mg and 300 mg strengths, and administered only by healthcare professionals in a clinic setting. The product carries a boxed warning and is available through a restricted distribution program under a Risk Evaluation and Mitigation Strategy (REMS), reflecting its schedule as a controlled substance and the need to monitor for serious risks like intravenous self-administration.
Indivior and long-acting opioid treatments
For investors tracking Indivior stock and its opioid use disorder franchise, Sublocade sits alongside legacy products in a portfolio that targets long-term treatment adherence and payer contracts.
How it is used in US clinics
In the United States, Sublocade is positioned as a maintenance therapy for patients who have already started on a daily transmucosal buprenorphine and reached a stable dose. After at least seven days of stabilization, a patient can transition to monthly Sublocade injections, typically starting with 300 mg monthly doses followed by maintenance at either 100 mg or continuing at 300 mg based on response.
In practice, that means treatment programs arrange monthly appointments, often bundling counseling and urine drug screening with the shot. In the Newark clinic, Dr. Alicia Morgan, an addiction specialist, tells us she likes the way Sublocade "takes the daily decision-making off the table" for some patients who struggle with adherence. She points to the injection tray and notes that her staff logs each dose as part of a REMS-compliant workflow.
Pricing, coverage and US access
For US patients and payers, the financial side of Sublocade matters as much as the clinical profile. Indivior lists the product on its patient support site with assistance programs and notes that Sublocade is reimbursed under both commercial insurance and Medicaid in many states. While wholesale acquisition cost is not shown directly in consumer materials, US trade reporting has indicated that once-monthly extended-release buprenorphine injections like Sublocade can run into the thousands of dollars per dose before insurance negotiations.
Indivior’s patient support page for Sublocade offers information on copay assistance and access navigators for eligible patients. For many US clinics, especially those serving low-income populations, the ability to tap into manufacturer support and state-level coverage determines whether Sublocade becomes a staple therapy or stays reserved for a subset of insured patients. In conversations with program directors, they describe a patchwork landscape where some managed care plans actively prefer monthly injections for adherence, while others require prior authorization or step therapy.
Clinical profile and safety signals
From a medical standpoint, Sublocade’s differentiator is its controlled delivery of buprenorphine over a month, aiming for more stable plasma levels and fewer peaks and troughs than daily dosing. Indivior’s clinical trial data, summarized in its prescribing information, showed statistically significant reductions in illicit opioid use compared with placebo in adults with moderate to severe opioid use disorder. The trials measured urine drug screens and self-reported use over time, aligning with how regulators evaluate OUD treatments.
Side effects are consistent with buprenorphine and injection-site reactions. Common adverse events include constipation, headache, nausea, injection-site pain, and insomnia. The labeling also flags risks such as hepatic enzyme elevation and potential for life-threatening respiratory depression when combined with other CNS depressants. Because Sublocade forms a solid depot in the abdomen, the REMS program and boxed warning stress that it must not be injected intravenously; doing so could cause occlusion or damage to blood vessels. Dr. Morgan says she takes time to show patients a diagram from the prescribing information so they understand why the injection is strictly subcutaneous.
Indivior’s strategy and product positioning
Indivior, which historically built its franchise around sublingual buprenorphine films like Suboxone, now treats Sublocade as a core growth pillar in its opioid use disorder portfolio. In its recent investor presentations, CEO Mark Crossley has highlighted the growth trajectory of Sublocade in the US, pointing to rising treatment numbers and expanded access in Medicaid programs as well as commercial plans. The company frames the product as part of a broader move toward long-acting formulations that can support durable remission and reduce diversion risk compared with take-home daily doses.
For US investors, that positioning matters because OUD treatments are both a mission-driven business and a revenue engine in a structurally growing market. US overdose statistics and policy initiatives continue to push for more medication-assisted treatment capacity. Indivior is betting that monthly depot formulations like Sublocade can capture a meaningful share of that demand. In presentations, management has noted ongoing work to deepen payer contracts and optimize clinic onboarding, indicating that Sublocade is not just a specialty product but a strategic pillar in the long-term business plan.
Company context and stock lens
Indivior is headquartered in the UK but focuses heavily on the US for Sublocade, where the opioid use disorder market and reimbursement infrastructure are most developed. The product sits alongside other treatments in the company’s addiction portfolio, giving Indivior a multi-layered presence in opioid therapy. For retail investors watching Indivior stock (NASDAQ: INDV), Sublocade has become one of the central branded assets driving the company’s US revenue mix.
Key facts on Sublocade
- Product: Sublocade (buprenorphine extended-release injection)
- Manufacturer: Indivior PLC
- Category: Bestsellers & Flagships (opioid use disorder treatment)
- Launch: FDA approval in the US in 2017 for adult patients with moderate to severe opioid use disorder stabilized on transmucosal buprenorphine
- MSRP / Price: Exact list price not publicly disclosed in consumer materials; US wholesale pricing reported in trade channels in the low-thousands of USD per monthly dose before insurance negotiation
- Availability: Prescription-only in the US, administered in clinics and treatment programs under a REMS restricted distribution program
- Target audience: Adult patients with moderate to severe opioid use disorder who have achieved stability on daily transmucosal buprenorphine and are candidates for long-acting maintenance therapy
- Standout / USP: Once-monthly subcutaneous buprenorphine depot that is administered by healthcare professionals, designed to support adherence and reduce daily dosing burden with controlled, sustained plasma levels over one month
This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.
